Price
No data yet.
Social Signal Score
Revenue
$102.43M+960.39%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael C. Kavanagh
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 470
- Beta
- 1.20
- Country
- AU
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 12.74
Financials
Revenue
$102.43M+960.4%Net Income
$9.64MEBITDA
$12.81MFree Cash Flow
$4.34MEPS (diluted)
$0.03Shares Outstanding (diluted)
308.87M+18.6%Operating Expenses
$69.51MCash & Debt
$159.76MReturn of Capital
$4.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $198.93M | $20.68M | $0.07 |
| 2024 | $170.01M | $12.97M | $0.04 |
| 2023 | $167.51M | $19.88M | $0.07 |
| 2022 | $119.73M | $3.74M | $0.01 |
| 2021 | $103.08M | $8.58M | $0.03 |
| 2020 | $99.38M | $10.14M | $0.03 |
| 2019 | $84.06M | $13.60M | $0.05 |
| 2018 | $60.65M | $5.75M | $0.02 |
| 2017 | $67.51M | $26.16M | $0.09 |
| 2016 | $42.80M | $122.0K | $0.00 |
| 2015 | $22.21M | $-5.46M | $-0.02 |
| 2014 | $21.49M | $-2.60M | $-0.01 |
| 2013 | $14.90M | $-5.77M | $-0.02 |
| 2012 | $12.30M | $-4.68M | $-0.02 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.10
- Implied price
- $5.21
- Return from $2.30
- 17.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.59 — today's price is already 11.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 36 | 44 | 52 | 60 | 68 |
|---|---|---|---|---|---|
| -2.0% | -0.7% | 3.3% | 6.8% | 10.0% | 12.7% |
| 3.0% | 4.3% | 8.6% | 12.3% | 15.6% | 18.5% |
| 8.0% | 9.4% | 13.9% | 17.8% | 21.2% | 24.2% |
| 13.0% | 14.5% | 19.2% | 23.2% | 26.8% | 30.0% |
| 18.0% | 19.5% | 24.4% | 28.7% | 32.4% | 35.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·7h ago·Positive
Nanosonics Limited (NNCSF) Q4 2026 Earnings Call Transcript Nanosonics Limited (NNCSF) Q4 2026 Earnings Call Transcript
View source ↗
Earnings
Tue, Feb 23(in 6 months)
Consensus estimate $0.02 per share
Typical surprise +22.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 25$0.02 vs $0.02beat
- Tue, Feb 24$0.02 vs $0.02miss
- Sun, Aug 24$0.02 vs $0.02beat
- Wed, Feb 19$0.02 vs $0.01beat
- Mon, Aug 26$0.01 vs $0.01beat
- Mon, Feb 26$0.01 vs $0.01beat
Estimates and results for NNCSF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.